Gerald Clarke | 07/31/2013
Jürgen Blusch, Head of Cell Substrate Analytics at Novartis speaks to Pharma IQ on the topics of mitigating risk in pathogen safety, new technologies and techniques such as nucleic acid based techniques for safety testing. He also spoke about what is limiting the uptake of these promising techniques.
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More